Although some guidelines have challenged the role of Metformin as the first-line glucose-lowering drug, it is important to note that the cardiovascular-renal protective effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were observed in patients with type 2 diabetes, the majority of whom were treated with Metformin
Guided programs like John Peels GLP-1 Strength Support can make strength training more approachable
Lifelong injections may be required
Headache is reported by some users, typically mild and decreasing with continued use
doi: 10.3389/fphar.2025.1516601 Received 24 October 2024 Accepted 04 February 2025 Published 24 February 2025 Volume 16 - 2025 Edited by Ewa Litwa, Polish Academy of Sciences, Poland Reviewed by Stefano Comai, University of Padua, Italy Archita Venugopal Menon, Beam Therapeutics, United States Updates Copyright 2025 Zhao, Ren, Luo, Li, Cheng, Wen, Wu and Zhou
Tali informazioni non necessariamente traggono origine da dati scientifici clinicamente dimostrati, ma posso provenire anche solamente dalluso erboristico tradizionale o da ricerche empiriche non confermate scientificamente, senza unadeguata verifica della corrispondenza tra gli studi su singole piante o ingredienti e le reali attivit degli stessi sulluomo
